Valproic Acid and Lithium Meditate Anti-Inflammatory Effects by Differentially Modulating Dendritic Cell...

Area of Science:

• Immunology
• Pharmacology
• Cell Biology

Background:

• Valproic acid (VPA) and lithium are mood stabilizers and anticonvulsants.
• Both VPA and lithium inhibit Glycogen Synthase Kinase (GSK)-3.
• VPA also inhibits histone deacetylase (HDAC).

Purpose of the Study:

• To compare the immunomodulatory activities of VPA and lithium.
• To investigate their effects on dendritic cell (DC) differentiation and function.
• To explore their potential in treating inflammation-related diseases.

Main Methods:

• Mice models of collagen-induced arthritis triggered by lipopolysaccharide (LPS).
• Analysis of serum cytokine levels (IL-6, IL-10).
• In vitro studies on human monocyte-derived immature dendritic cells (DCs) treated with VPA or lithium, assessing surface marker expression (CD1, CD83, CD86) and cytokine secretion (IL-6, IL-8, IL-10, TNF-α, IL-23).
• Evaluation of DC's capacity to promote T helper 17 cell differentiation.

Main Results:

• VPA and lithium alleviated arthritis severity and reduced serum IL-6 and IL-10 levels in mice.
• Both agents downregulated CD1 expression and IL-6 secretion during DC differentiation.
• VPA and lithium differentially affected CD83, CD86 expression, and secretion of IL-8, IL-10, TNF-α, and IL-23.
• VPA-treated DCs showed reduced capacity to induce T helper 17 cell differentiation.

Conclusions:

• VPA and lithium differentially modulate DC function and T cell responses.
• These agents may offer complementary immunomodulatory effects for treating inflammation-related diseases.
• Further research into their distinct mechanisms is warranted.